Skip to main content
Top
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis

Authors: Ou Huang, Min Jiang, Xi Zhang, Xiaosong Chen, Jiayi Wu, Kunwei Shen

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Many studies were published to assess the association between FASLG T844C polymorphism and susceptibility to breast cancer, but the data were controversial. A meta-analysis was performed to assess the association comprehensively. We performed a comprehensive search in PubMed, Embase, and Web of Science to find eligible studies. Six studies with a total of 6,784 participants were finally included into the meta-analysis. There were a total of 3,382 cases with breast cancer and 3,402 controls in those six studies. Odds ratio (OR) with 95 % confidence interval (95 %CI) was used to evaluate the association. Overall, there was an obvious association between FASLG T844C polymorphism and breast cancer under all four contrast models (for C versus T: OR = 1.26, 95 %CI 1.05–1.50, P OR = 0.011; for CC versus TT: OR = 1.42, 95 %CI 1.11–1.81, P OR = 0.005; for CC versus TT/TC: OR = 1.41, 95 %CI 1.06–1.88, P OR = 0.019; for CC/TC versus TT: OR = 1.16, 95 %CI 1.01–1.33, P OR = 0.038). In the subgroup analysis by ethnicity, there was an obvious association between FASLG T844C polymorphism and breast cancer in Asians, but there was no obvious association in Caucasians. The meta-analysis suggests that there is an association between FASLG T844C polymorphism and susceptibility to breast cancer, especially in Asians.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
go back to reference Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10:205–12.PubMedCrossRef Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10:205–12.PubMedCrossRef
4.
go back to reference Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.PubMedCrossRef Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.PubMedCrossRef
5.
go back to reference Campa D, McKay J, Sinilnikova O, Husing A, Vogel U, Hansen RD, et al. Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk. Breast Cancer Res Treat. 2009;118:565–74.PubMedCrossRef Campa D, McKay J, Sinilnikova O, Husing A, Vogel U, Hansen RD, et al. Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk. Breast Cancer Res Treat. 2009;118:565–74.PubMedCrossRef
6.
go back to reference van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71–88.CrossRef van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71–88.CrossRef
7.
go back to reference Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz). 2013;61:43–58.CrossRef Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz). 2013;61:43–58.CrossRef
8.
go back to reference Denis CJ, Deiteren K, Hendriks D, Proost P, Lambeir AM. Carboxypeptidase m in apoptosis, adipogenesis and cancer. Clin Chim Acta. 2013;415:306–16.PubMedCrossRef Denis CJ, Deiteren K, Hendriks D, Proost P, Lambeir AM. Carboxypeptidase m in apoptosis, adipogenesis and cancer. Clin Chim Acta. 2013;415:306–16.PubMedCrossRef
9.
go back to reference Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol. 2009;647:64–93.PubMedCrossRef Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol. 2009;647:64–93.PubMedCrossRef
10.
go back to reference Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:85–101.PubMedCrossRef Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:85–101.PubMedCrossRef
11.
go back to reference Lettau M, Paulsen M, Schmidt H, Janssen O. Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol. 2011;90:456–66.PubMedCrossRef Lettau M, Paulsen M, Schmidt H, Janssen O. Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol. 2011;90:456–66.PubMedCrossRef
12.
go back to reference Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010;49:944–50.PubMedCrossRef Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010;49:944–50.PubMedCrossRef
13.
go back to reference Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, et al. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res. 2011;17:5991–9.PubMedCrossRef Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, et al. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res. 2011;17:5991–9.PubMedCrossRef
14.
go back to reference Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004;96:1478–9. author reply 1479.PubMedCrossRef Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004;96:1478–9. author reply 1479.PubMedCrossRef
15.
go back to reference Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28:2548–51.PubMedCrossRef Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28:2548–51.PubMedCrossRef
16.
go back to reference Zhang B, Sun T, Xue L, Han X, Lu N, Shi Y, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28:1067–73.PubMedCrossRef Zhang B, Sun T, Xue L, Han X, Lu N, Shi Y, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28:1067–73.PubMedCrossRef
17.
go back to reference Mahfoudh W, Bouaouina N, Gabbouj S, Chouchane L. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the tunisian population. Hum Immunol. 2012;73:932–8.PubMedCrossRef Mahfoudh W, Bouaouina N, Gabbouj S, Chouchane L. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the tunisian population. Hum Immunol. 2012;73:932–8.PubMedCrossRef
18.
go back to reference Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3:625–8.PubMedCentralPubMed Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3:625–8.PubMedCentralPubMed
19.
go back to reference Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer—pilot study of 134 cases. PLoS One. 2013;8:e53075.PubMedCentralPubMedCrossRef Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer—pilot study of 134 cases. PLoS One. 2013;8:e53075.PubMedCentralPubMedCrossRef
20.
go back to reference Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
21.
22.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
23.
go back to reference Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
24.
go back to reference Gong WF, Zhong JH, Xiang BD, Ma L, You XM, Zhang QM, et al. Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases. PLoS One. 2013;8:e60108.PubMedCentralPubMedCrossRef Gong WF, Zhong JH, Xiang BD, Ma L, You XM, Zhang QM, et al. Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases. PLoS One. 2013;8:e60108.PubMedCentralPubMedCrossRef
25.
go back to reference Yang Z, Shen J, Cao Z, Wang B. Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk. Breast Cancer Res Treat. 2013;139:267–75.PubMedCrossRef Yang Z, Shen J, Cao Z, Wang B. Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk. Breast Cancer Res Treat. 2013;139:267–75.PubMedCrossRef
26.
go back to reference Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian HP, et al. FASLG polymorphism is associated with cancer risk. Eur J Cancer. 2009;45:2574–8.PubMedCrossRef Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian HP, et al. FASLG polymorphism is associated with cancer risk. Eur J Cancer. 2009;45:2574–8.PubMedCrossRef
Metadata
Title
FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis
Authors
Ou Huang
Min Jiang
Xi Zhang
Xiaosong Chen
Jiayi Wu
Kunwei Shen
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1145-9

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine